The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
|Articles|January 20, 2017
Supplements and Featured Publications
- Diabetes Compendium: Issue 2
Diabetes Compendium: Issue 2
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Who Recommends COVID-19 Vaccines Without ACIP?
5